---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020175"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:27:11.036693+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q4 revenue $81.2M (+159% YoY); guides FY2024 $360-370M

## Summary
- Q4 2023 revenue $81.2M (+159% YoY); net income $4.0M ($0.12 EPS) vs loss of $6.7M in Q4 2022.
- Full-year 2023 revenue $241.6M (+159% YoY); net loss narrowed to $25.0M from $36.2M.
- Gross margin declined to 59% (Q4) and 64% (FY) from 66% and 70% respectively.
- Cash position $394.8M as of Dec 31, 2023.
- FY2024 revenue guidance $360-370M, representing 49%-53% growth over 2023.

## SEC filing metadata
- accession: 0000950170-24-020175
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/tmdx-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020175
- JSON: https://secwatch.observer/filing/0000950170-24-020175.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020175.txt

## Key facts
- Earnings Releases
  TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.
  - Period: the year ended December 31, 2023
  - Revenue: $241.6 million
  - Net income: $(25.0) million
  - Result: reported results
  source text: December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm
- Earnings Releases
  TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.
  - Period: full-year 2024
  - Revenue: $360 million to $370 million
  - Guidance: initiated
  - Result: guidance update
  source text: TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm
- Earnings Releases
  TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.
  - Period: the quarter ended December 31, 2023
  - Revenue: $81.2 million
  - Net income: $4.0 million
  - EPS: $0.12 per share
  - Result: reported results
  source text: patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.